The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.
C. Neuzillet
No relevant relationships to disclose
O. Hentic
No relevant relationships to disclose
B. Rousseau
No relevant relationships to disclose
V. Rebours
No relevant relationships to disclose
L. Bengrine-Lefèvre
No relevant relationships to disclose
F. Bonnetain
No relevant relationships to disclose
E. Raymond
No relevant relationships to disclose
P. Ruszniewski
No relevant relationships to disclose
C. Louvet
No relevant relationships to disclose
P. Hammel
No relevant relationships to disclose